JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

Home・Aandelen Lijst・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

35.73 -5.75

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

35.63

Max

37.61

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.4M -81M
EPS	-0.5
Werknemers	205
EBITDA	-6.8M -79M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+40.16% upside

Dividenden
By Dow Jones
Volgende Winsten	24 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.6B 5.8B
Vorige openingsprijs	41.48
Vorige sluitingsprijs	35.73

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

4.88 / 5.87 Steun & Weerstand

Cogent Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 feb 2026, 23:11 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Winsten

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisities, Fusies, Overnames

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisities, Fusies, Overnames

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisities, Fusies, Overnames

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Marktinformatie

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Winsten

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Winsten

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Winsten

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Winsten

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Winsten

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Winsten

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Marktinformatie

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Vergelijking

Prijswijziging

Cogent Biosciences Inc Prognose

Koersdoel

By TipRanks

40.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 50.33 USD 40.16%

Hoogste 67 USD

Laagste 34 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cogent Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Gebaseerd op 13 analisten die aandelenratings hebben gegeven aan Cogent Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

4.88 / 5.87Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.